Week in Review: The Latest from PhRMA

Priscilla VanderVeer
Priscilla VanderVeer July 17, 2015

Week in Review: The Latest from PhRMA.

Share This

week-in-reviewNeurological Disorders: America’s biopharmaceutical companies are committed to developing innovative new treatments for the nearly 50 million Americans affected by neurological disorders. This week, PhRMA highlighted that commitment with a series of events and reports, including:

  • The Medicines in Development for Neurological Disorders report from PhRMA and the Epilepsy Foundation, which found that there are currently 420 medicines in the pipeline to combat disorders of the brain, spinal cord and nerves.
  • The Researching Alzheimer’s Disease: Setbacks and Stepping Stones report that highlights the disappointments, but also the encouraging progress on, the path toward new treatments for this devastating disease.
  • Dr. Bill Chin of PhRMA moderated a panel of health care experts for a live webcast discussion about the current state of research to treat and care for Alzheimer’s disease and viewers contributed questions using hashtag #Alz15.

Biopharmaceuticals in Government Programs: Check out PhRMA’s new chart pack, which includes key facts about prescription medicines in four major government programs – Medicare, Medicaid, Veterans Affairs and the 340B drug discount program.

Burden on Patients: This week we sat down with the American Cancer Society Cancer Action Network to discuss access to oncology medicines in exchange plans in 2015.

ICYMI: Panel of doctors say new hep C treatments are cost effective: A recent Bloomberg story reports that new treatments for hepatitis C are cost-effective. Learn more here.

#MedicareMonday: This past Monday was the 2015 White House Conference on Aging and PhRMA released a new video on how patients benefit from Medicare Part D. Watch the video and stay tuned for more on this landmark program as we prepare to celebrate its 50th birthday later this month!

Topics: Alzheimer's